BBT003 / Bambusa Therapeutics - LARVOL DELTA

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs (PRNewswire) - "Key uses of proceeds: Advance BBT003 and BBT004 through IND-enabling studies and into early clinical development, maintaining Bambusa's pace of advancement. Broaden Bambusa's bispecific antibody platform into new I&I indications and deepen the pipeline. Strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones."

Financing • Immunology • Rheumatology

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases (PRNewswire) - "Bambusa Therapeutics, Inc...today announced the successful completion of its oversubscribed Series A financing of approximately $90 million. The round was led by new investor RA Capital Management, with participation from new investors including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management. All existing investors also participated. The funding will support the advancement of Bambusa's lead programs through Phase I trials and drive further pipeline development...Two of Bambusa's four programs are on track to enter the clinic in Q1 2025 and mid-2025, respectively. BBT001...intended to supplant the current standard of care for a range of dermatological conditions. BBT002...created as a 'platform in a molecule' with applications across respiratory, dermatology, and gastroenterology indications...BBT003 and BB004, also have best-in-disease potential in the inflammatory bowel diseases and rheumatological indications."

Financing • New P1 trial • Dermatology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Rheumatology